| Treatment for 14 days with Proteostasis Therapeutics’ PTI-801 in cystic fibrosis (CF) patients also being treated with Orkambi (lumacaftor/ivacaftor) led to statistically significant improvements in sweat chloride, body mass index, and rescued blood glucose levels in a subgroup of patients with diabetes, Phase 1 trial data show. PTI-801 is being tested in a 14-day study in adults with […] The post #ECFS2018 – Potential CFTR Corrector PTI-801, Plus Orkambi, Seen to Treat CF Patients in Phase 1 Trial appeared first on Cystic Fibrosis News Today. | ||
|
No hay comentarios:
Publicar un comentario